MedPath

Docetaxel

Generic Name
Docetaxel
Brand Names
Taxotere, Docetaxel Accord, Docetaxel Kabi
Drug Type
Small Molecule
Chemical Formula
C43H53NO14
CAS Number
114977-28-5
Unique Ingredient Identifier
699121PHCA
Background

Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel. Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiometric ratio, allowing it to prevent cell division and promote to cell death. Compared to paclitaxel, docetaxel is two times more potent as an inhibitor of microtubule depolymerization. Docetaxel binds to microtubules but does not interact with dimeric tubulin.

The use of docetaxel may lead to udesired outcomes such as hepatic impairment, hematologic effects, enterocolitis and neutropenic colitis, hypersensitivity reactions, fluid retention, second primary malignancies, embryo-fetal toxicity, and tumor lysis syndrome. Docetaxel was approved by the FDA in 1996 and is available in solution for injection for intravenous or parenteral administration.

Indication

Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC. For the treatment of metastatic castration-resistant prostate cancer, docetaxel is indicated with prednisone. Docetaxel is also indicated with cisplatin and fluorouracil for untreated, advanced gastric adenocarcinoma, including the gastroesophageal junction, and with cisplatin and fluorouracil for induction treatment of locally advanced squamous cell carcinoma of the head and neck (SCCHN).

Associated Conditions
Esophageal Cancer, Ewing's Sarcoma, Locally Advanced Breast Cancer (LABC), Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Node Positive Breast Cancer, Ovarian Cancer Metastatic, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Advanced untreated gastric adenocarcinoma, Locally advanced Squamous cell carcinoma of head and neck, Locally advanced untreated non small cell lung cancer, Metastatic untreated non small cell lung cancer, Refractory, locally advanced Non small cell lung cancer, Refractory, metastatic Non small cell lung cancer, Refractory, metastatic hormone-refractory Prostate cancer
Clinical Trials
Related News

NUBEQA Shows Strong Efficacy in Metastatic Prostate Cancer Subgroups, New Trial Data Reveals

• New ARANOTE trial data demonstrates NUBEQA plus ADT reduced risk of disease progression by 70% in low-volume metastatic hormone-sensitive prostate cancer patients and 40% in high-volume disease patients. • Subgroup analysis of ARASENS trial confirms NUBEQA's benefits across age groups, showing consistent survival improvements in both patients under and over 75 years old. • Real-world analysis indicates NUBEQA combination therapy results in lower treatment discontinuation rates and better PSA responses compared to alternative treatments.

FDA Reviews Pertuzumab Biosimilar HLX11 for HER2-Positive Breast Cancer Treatment

• Shanghai Henlius Biotech's pertuzumab biosimilar HLX11 has received FDA acceptance of its Biologics License Application for HER2-positive breast cancer treatment, supported by comprehensive clinical trials. • Phase 1 study demonstrated comparable pharmacokinetics, safety, and immunogenicity between HLX11 and reference pertuzumab across US, EU, and Chinese versions of the drug. • Phase 3 trial successfully met its primary endpoint of total pathological complete response in HER2-positive, hormone receptor-negative early or locally advanced breast cancer patients.

Nab-Paclitaxel Plus HER2 Blockade Improves Response in Early Breast Cancer

• A phase 3 trial (HELEN-006) showed that neoadjuvant nab-paclitaxel with trastuzumab and pertuzumab led to a higher pathologic complete response (pCR) rate compared to docetaxel plus carboplatin in HER2-positive early breast cancer. • The nab-paclitaxel regimen achieved a pCR rate of 66.3% versus 57.6% with the docetaxel-carboplatin regimen (OR, 1.54; 95% CI, 1.10-2.14) at a median follow-up of 26 months. • Patients receiving nab-paclitaxel experienced fewer grade 3/4 adverse events, including nausea, diarrhea, and neuropathy, suggesting improved tolerability without compromising efficacy. • The study suggests nab-paclitaxel could be a preferred neoadjuvant option with dual HER2 blockade for HER2-positive early-stage breast cancer due to its improved pCR rates and reduced toxicity.

Error parsing response

Error occurred while parsing the model response.

Vivesto's Paccal Vet Receives Limited Market Classification in EU for Canine Hemangiosarcoma

• Vivesto AB's Paccal Vet received Limited Market classification from the EMA for treating splenic hemangiosarcoma in dogs after splenectomy, potentially expediting EU approval. • The Limited Market classification, similar to the US MUMS designation, offers benefits like reduced data requirements and enhanced regulatory assistance. • Paccal Vet, a paclitaxel formulation using Vivesto's XR-17 technology, has demonstrated good safety in previous canine cancer studies. • If approved, Paccal Vet would receive 10 years of market protection from generic competition within the EU, addressing a significant unmet need.

Gilead Withdraws Trodelvy's Bladder Cancer Indication Following Trial Failure

• Gilead Sciences is voluntarily withdrawing Trodelvy from the U.S. market for advanced urothelial carcinoma after failing its confirmatory Phase 3 TROPiCS-04 trial. • The TROPiCS-04 study did not meet its primary endpoint of overall survival, leading to the decision in consultation with the FDA. • Trodelvy remains approved for other indications, including triple-negative and HR-positive/HER2-negative breast cancer, and its ongoing trials will continue. • The accelerated approval granted in 2021 was contingent on the confirmatory trial, highlighting the FDA's increasing vigilance regarding accelerated approvals.

Neoadjuvant Chemohormonal Therapy Shows Promise for High-Risk Prostate Cancer

Recent studies suggest that neoadjuvant chemohormonal therapy (NCHT) could improve outcomes for patients with high-risk localized prostate cancer (PCa). Despite the potential for increased adverse events and economic burdens, NCHT, particularly with the addition of docetaxel, has shown to be effective in reducing tumor burden and improving survival rates. The importance of patient selection, pathological response evaluation, and the use of predictive biomarkers and PSMA PET/CT imaging are highlighted as crucial factors in optimizing treatment strategies.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy